Vestal Point Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vestal Point Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-750,000	Closed	-$31.2M	–	87
2025 Q3	$31.2M	Sell	750,000 -750,000	-50%	-$24M	1.41%	28
2025 Q2	$43.1M	Hold	1,500,000	–	–	2.27%	16
2025 Q1	$50.3M	Buy	+1,500,000	New	+$56M	3.59%	8
2024 Q4	–	Sell	-205,000	Closed	-$10.5M	–	82
2024 Q3	$10.5M	Buy	+205,000	New	+$10.6M	0.79%	32
2024 Q1	–	Sell	-450,000	Closed	-$16M	–	63
2023 Q4	$16M	Buy	+450,000	New	+$13.8M	1.7%	20

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vestal Point Capital's CRNX Position: Q4 2025 in Review

Vestal Point Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 750,000 shares — an estimated $31.2M sold.

Vestal Point Capital first reported a position in CRNX in Q4 2023 and held it in 5 quarters. The position peaked at $50.3M in Q1 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Vestal Point Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Vestal Point Capital sold 750,000 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $31.2M.
Vestal Point Capital first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Vestal Point Capital's Crinetics Pharmaceuticals position peaked at $50.3M in Q1 2025.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.